Literature DB >> 17879529

[Study on changes of TCM syndrome in patients with coronary heart disease before and after intervention treatment].

Bo-jun Chen1, Zong-qi Pan, Xue-xu Su.   

Abstract

OBJECTIVE: To observe the changing laws of TCM syndrome type in patients with coronary heart disease (CHD) before and after intervention treatment (IT) and to explore the influence of IT on TCM syndrome type.
METHODS: The TCM syndrome type of 71 patients with "Chest-Bi" was differentiated before and after percutaneous coronary intervention (PCI) treatment, of which the most common syndrome types were qi deficiency, yang deficiency, yin deficiency, qi stagnation, blood stasis, phlegm, cold coagulation, heat-syndrome, etc.
RESULTS: Before PCI treatment, syndrome types of blood stasis (53 cases, 74.6%), qi deficiency (46 cases, 64.8%), and phlegm (28 cases, 39.4%) were the commonest, while there were 12 cases of qi stagnation (16.9%) and 12 cases of cold coagulation (16.9%); One week after PCI treatment, the most commonly seen types were blood stasis (47 cases, 66.2%), qi deficiency (39 cases, 54.9%) and phlegm (23 cases, 32.4%), while qi stagnation (2 cases, 2.8%) and cold coagulation (1 case, 1.4%) were also found; One month after PCI, qi deficiency (47 cases,85.4%), blood stasis (40 cases,72.7%), phlegm (31 cases, 56.4%) were the most commonly seen types. Comparison of the syndrome types between before and after PCI showed that the syndromes of qi deficiency and phlegm were progressively aggravating, while syndromes of qi stagnation and cold coagulation were alleviated after PCI.
CONCLUSION: Although PCI treatment could relieve patients' symptoms of excess in superficiality, it can't radically change the pathogenetic nature of CHD, namely, the deficiency in origin and excess in superficiality, which indicates that one should pay full attention to the importance and necessity of CHD after PCI treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17879529

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  6 in total

1.  Comparison of Aspirin and Naoxintong Capsule () with Adjusted-Dose Warfarin in Elderly Patients with High-Risk of Non-Valvular Atrial Fibrillation and Genetic Variants of Vitamin K Epoxide Reductase.

Authors:  Huan Wang; Xiao-Kai Zhou; Li-Fan Zheng; Xiao-Ying Wu; Hui Chen
Journal:  Chin J Integr Med       Date:  2016-02-26       Impact factor: 1.978

2.  Integrative Medicine Intervention for Chronic Disease Management-Cardiovascular Disease.

Authors:  Da-Zhuo Shi
Journal:  Chin J Integr Med       Date:  2018-11-24       Impact factor: 1.978

3.  Comparison of Adjunctive Naoxintong versus Clopidogrel in Volunteers with the CYP2C19*2 Gene Mutation Accompanied with Qi Deficiency and Blood Stasis Constitution.

Authors:  Hui Chen; Guangwei Yu; Hong Sun; Xiaoying Wu; Huan Wang
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-01       Impact factor: 2.629

4.  Correlation between Traditional Chinese Medicine Syndromes and Type 2 Myocardial Infarction in Critically Ill Patients with Pulmonary Disease.

Authors:  Sheng-Li Ma; Shan-You Hu; Wu-Lin Li; Da-Li You; Ting-Ting Jiang; Li Wang; Fei Wang; Xiao Wu
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-21       Impact factor: 2.629

5.  The effects of xuefu zhuyu and shengmai on the evolution of syndromes and inflammatory markers in patients with unstable angina pectoris after percutaneous coronary intervention: a randomised controlled clinical trial.

Authors:  Jie Wang; Xiaochen Yang; Fuyong Chu; Jianxin Chen; Qingyong He; Kuiwu Yao; Fei Teng; Yonghong Gao; Yanhui Xing; Aiming Wu; Yanwei Xing
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

6.  Correlation Analysis between Traditional Chinese Medicine Syndromes and Gastrointestinal Bleeding after Percutaneous Coronary Intervention.

Authors:  Chenhao Zhang; Chaolian Huang; Mingming Wang; Xiaolin Kong; Guannan Liu; Jie Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-05-31       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.